QbD Group
    Regulatory Update

    Latest Update on Appendix 1 of the Nitrosamine Guidelines

    On 01/05/2024, the European Medicines Agency (EMA) rolled out an update to Appendix 1 (EMA/154403/2024 /Rev. 4) of the Nitrosamines Guideline. In this Appendix the different nitrosamines that have an established Acceptable Intake (AI) are listed. This update particularly impacts medicines containing any of the active substances listed above in their formulation.

    2024年5月14日2 分钟阅读
    On 01/05/2024, the European Medicines Agency (EMA) rolled out an update to Appendix 1 (EMA/154403/2024 /Rev. 4) of the Nitrosamines Guideline. In this Appendix the different nitrosamines that have an established Acceptable Intake (AI) are listed.

    What’s new?

    In this update, new nitrosamine drug substance-related impurities (NDSRIs) of high concern, such as N-nitroso-N-ethyl-benzylamine (NBEA), N-nitroso-desmethyl-edoxaban and N-nitroso-trientine Impurity 1, have been published. As well as other NDSRIs related to the manufacturing process of various medicines (Opipramol, Omecamtiv mecarbil, Mirabegron, Articaine, Fenfluramine, Dextromethorphan, Posaconazole, Rivaroxaban and Vibegron).

    In addition, the AI value for N-nitroso-Lisinopril has been updated. It’s no longer considered a mutagenic impurity, and can therefore be controlled according to ICH Q3B.

    What does this mean to you?

    In recent years, significant concern has arisen due to the well-known carcinogenic potency of nitrosamine impurities. Consequently, regulatory agencies have reiterated the need for continuous review of Nitrosamine Risk Assessments. Therefore, when updates like this are published, it’s essential to pause and ensure that your reports comply with current regulations and that all potential risk factors have been accurately assessed.

    This update particularly impacts medicines containing any of the active substances listed above in their formulation. If this applies to you, the first question to ask is, “Have I assessed the possible presence of these new NDRSIs?” If the answer is “no,” it’s crucial to promptly review your NRA, as there may be new risks that weren’t considered previously.

    If you have already assessed these NDRSIs and identified a risk, your next step is to check whether the AI value used for calculating the acceptable limits has changed with this update. The limits may have changed significantly, potentially altering the conclusions of your confirmatory analysis results.

    How can QbD Group assist you regarding this update?

    Our expert team toxicologists and organic chemists is here to guide you through regulatory changes and ensure your Nitrosamine Risk Assessments are up-to-date and compliant.

    关于作者

    Pablo Palomar
    Pablo Palomar

    Senior Toxicology Officer

    Toxicology services

    Get Expert Toxicology Assessments

    QbD Group offers a set of Toxicology services, for your processes, applications, and equipment. We are EUROTOX certified and are members of AETOX.

    Read more
    分享本文

    订阅生命科学领域的最新动态

    专家观点直达您的收件箱——选择您的兴趣。

    绝无垃圾邮件。随时取消订阅。

    继续阅读

    相关内容

    我们使用 Cookie 来改善您的体验

    我们使用必要的 Cookie 来保证网站功能,以及可选的分析 Cookie 来改善我们的服务。 阅读我们的 隐私政策Cookie 政策.